Data Sheet (Cat.No.T200221)

TargetMol

JNK-1-IN-3

Chemical Properties



CAS No. : 3056388-71-4

Formula: C19H17FN4O3

Molecular Weight: 368.36

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNK-1-IN-3 (Compound 9e) is a JNK1 inhibitor that downregulates JNK1 and phosphorylated JNK1, reduces c-Jun and c-Fos expression in tumours, and restores p53 activity. JNK-1-IN-3 exhibits potent antiproliferative activity against renal carcinoma and breast cancer cell lines.
Targets(IC50)	MMP,JNK,p53

Solubility Information

Solubility	DMSO: 80 mg/mL (217.18 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (13.57 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7147 mL	13.5737 mL	27.1474 mL
5 mM	0.5429 mL	2.7147 mL	5.4295 mL
10 mM	0.2715 mL	1.3574 mL	2.7147 mL
50 mM	0.0543 mL	0.2715 mL	0.5429 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Shaalan M M, et al. Novel 3, 6-Disubstituted Pyridazine Derivatives Targeting JNK1 Pathway: Scaffold Hopping and Hybridization-Based Design, Synthesis, Molecular Modeling, and In Vitro and In Vivo Anticancer Evaluation[J]. ACS Omega, 2024.